Kairos Pharma Ltd. (NYSE American: KAPA) provided a business update and outlook into 2025 through a letter to its shareholders. The letter highlighted key milestones achieved in 2024, which focused on building the foundational infrastructure necessary for the company's entry into the public markets.
The company expressed confidence in the paradigm-shifting potential of its therapeutics, which are based on breakthrough science. Kairos Pharma anticipates several key upcoming milestones for 2025, indicating a period of continued development and progress for its pipeline.
CEO John Yu conveyed gratitude to partners and shareholders, emphasizing the company's commitment to expanding its scientific endeavors and providing value to shareholders in both the near and long term. This update sets expectations for the company's strategic direction and operational focus for the year ahead.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.